Navigation Links
Telik Announces First Quarter 2008 Financial Results
Date:5/8/2008

e treatment of advanced ovarian cancer and non-small cell lung cancer. Telik's product candidates were discovered using its proprietary drug discovery technology, TRAP(R), which enables the rapid and efficient discovery of small molecule drug candidates.

This press release contains "forward-looking" statements, including statements regarding the future development of TELCYTA and TELINTRA. These forward-looking statements are based upon Telik's current expectations. There are important factors that could cause Telik's results to differ materially from those indicated by these forward-looking statements, including, among others, if clinical trials of TELCYTA or TELINTRA are delayed or unsuccessful, Telik's business would suffer, if Telik's competitors develop and market products that are more effective than its product candidates, or obtain marketing approval before Telik does, Telik's commercial opportunity will be reduced or eliminated, and if Telik does not obtain regulatory approval to market products in the U.S. and foreign countries, Telik will not be permitted to commercialize these product candidates. Detailed information regarding factors that may cause actual results to differ materially from the results expressed or implied by statements in this press release may be found in Telik's periodic filings with the Securities and Exchange Commission, including the factors described in the section entitled "Risk Factors" in its annual report on Form 10-K for the year ended December 31, 2007. Telik does not undertake any obligation to update forward-looking statements contained in this press release.

TELIK, the Telik logo, TELCYTA, TELINTRA and TRAP are trademarks or registered trademarks of Telik, Inc.

Telik, Inc.

Statements of Operations

(In thousands, except per share amounts)

(Unaudited)


'/>"/>

SOURCE Telik, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Telik Announces Presentation and Webcast at Bear Stearns Healthcare Conference
2. Telik Announces Presentation and Webcast at UBS Global Life Sciences Conference
3. Telik Announces Presentation and Webcast at JPMorgan Healthcare Conference
4. Telik Announces Year-End Financial Release, Conference Call and Webcast
5. Telik Announces Revised Date for Year-End Financial Release, Conference Call and Webcast
6. Telik Announces Fourth Quarter and 2007 Year End Financial Results and 2008 Guidance
7. Telik Presents Preclinical Data at 99th Annual Meeting of the American Association for Cancer Research
8. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
9. YM BIOSCIENCES ANNOUNCES COMPLIANCE WITH AIM RULE 26
10. Emisphere Technologies, Inc. Announces Pricing of Registered Direct Offering
11. BioLife Solutions Announces Exclusive CryoStor(TM) Supply Agreement With the New England Cryogenic Center, Inc.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/18/2014)... , Sept. 18, 2014  Neogen Corporation (Nasdaq: ... into a strategic agreement with Merck Animal Health to ... The Igenity Dairy Heifer Program consists of ... on the genetic potential of replacement dairy heifers. The ... is born, and is an excellent tool in the ...
(Date:9/18/2014)... 18, 2014 SeqLL Inc., the ... technology, announced today the closing of a $1M ... by Genomic Diagnostic Technologies, will increase the power ... , Founded in March 2013 by Daniel Jones, ... at Helicos BioSciences, SeqLL has continued to offer ...
(Date:9/18/2014)... touch in the course of a day - ... rely on the chemical industry to turn raw ... products into valuable chemicals that are the ingredients ... Sarina Sarina, who achieved outstanding progress in driving ... temperature using light instead of fossil fuels, has ...
(Date:9/18/2014)... York, NY (PRWEB) September 18, 2014 ... completed negotiations with Salem Realty Group and has acquired ... development space within the Salem Executive Complex adjacent to ... ceremony was held on Friday September 5th. Whitehouse Labs ... refit the entire space specifically for package testing. The ...
Breaking Biology Technology:Merck Animal Health to market Neogen's dairy genomic program 2SeqLL Closes Series-A Funding Round for Expansion of Single Molecule Sequencing 2Using solar energy to turn raw materials into ingredients for every day life 2Whitehouse Labs Announces Package Testing Laboratory Expansion 2Whitehouse Labs Announces Package Testing Laboratory Expansion 3Whitehouse Labs Announces Package Testing Laboratory Expansion 4
... Sept. 14 Savient Pharmaceuticals, Inc. (Nasdaq: ... Drug Administration (FDA) has approved KRYSTEXXA™ (pegloticase), a PEGylated ... chronic gout in adult patients refractory to conventional therapy. ... in patients who have failed to normalize serum uric ...
... SUNNYVALE, Calif., Sept. 14 Molecular Devices, Inc., ... analysis, today announced the launch of two new ... microplate readers, enabling the company to meet all ... future. (Logo:   http://photos.prnewswire.com/prnh/20100406/SF82092LOGO ) ...
... 2011 Fiscal Year Guidance -- HARBIN, China, Sept. 14 /PRNewswire-Asia-FirstCall/ -- ... ... ... var first_result; // Results are keyed by longUrl, so we need to grab the first one. for ...
Cached Biology Technology:FDA Approves KRYSTEXXA™ (pegloticase) for the Treatment of Chronic Gout in Adult Patients Refractory to Conventional Therapy 2FDA Approves KRYSTEXXA™ (pegloticase) for the Treatment of Chronic Gout in Adult Patients Refractory to Conventional Therapy 3FDA Approves KRYSTEXXA™ (pegloticase) for the Treatment of Chronic Gout in Adult Patients Refractory to Conventional Therapy 4FDA Approves KRYSTEXXA™ (pegloticase) for the Treatment of Chronic Gout in Adult Patients Refractory to Conventional Therapy 5FDA Approves KRYSTEXXA™ (pegloticase) for the Treatment of Chronic Gout in Adult Patients Refractory to Conventional Therapy 6FDA Approves KRYSTEXXA™ (pegloticase) for the Treatment of Chronic Gout in Adult Patients Refractory to Conventional Therapy 7FDA Approves KRYSTEXXA™ (pegloticase) for the Treatment of Chronic Gout in Adult Patients Refractory to Conventional Therapy 8Launch of Two New Platforms for Microplate Analysis Expands Reader Portfolio and Ensures Molecular Devices Readers Meet all Combinations of Customer Needs 2Launch of Two New Platforms for Microplate Analysis Expands Reader Portfolio and Ensures Molecular Devices Readers Meet all Combinations of Customer Needs 3Weikang Bio-Technology Issues 2010 and 2011 Fiscal Year Guidance 2Weikang Bio-Technology Issues 2010 and 2011 Fiscal Year Guidance 3Weikang Bio-Technology Issues 2010 and 2011 Fiscal Year Guidance 4Weikang Bio-Technology Issues 2010 and 2011 Fiscal Year Guidance 5Weikang Bio-Technology Issues 2010 and 2011 Fiscal Year Guidance 6Weikang Bio-Technology Issues 2010 and 2011 Fiscal Year Guidance 7Weikang Bio-Technology Issues 2010 and 2011 Fiscal Year Guidance 8
(Date:9/18/2014)... the International Space Station ever starts a "frequent flyers" ... status. Recently the orbiting laboratory has hosted increasing numbers ... returned from the space station in April, and another ... third experiment is planned to launch in December. , ... around the world-- and in space. Model organisms can ...
(Date:9/18/2014)... have built the first smartphone app that automatically ... trends. In other words, your smartphone knows your ... -- and how that affects you. , The ... and loneliness to their academic performance, also may ... example, to monitor mental health, trigger intervention and ...
(Date:9/18/2014)... devastated algal forests in the eastern Mediterranean Sea pose ... their distribution continues to expand as the climate warms, ... team of researchers led by Dr Adriana Vergs of ... Institute for Advanced Studies in Spain, is published in ... team surveyed more than 1000 kilometres of coastline in ...
Breaking Biology News(10 mins):Buzzing with activity: Fruit flies orbit Earth for science 2Buzzing with activity: Fruit flies orbit Earth for science 3Buzzing with activity: Fruit flies orbit Earth for science 4New Dartmouth smartphone app reveals users' mental health, performance, behavior 2New Dartmouth smartphone app reveals users' mental health, performance, behavior 3New Dartmouth smartphone app reveals users' mental health, performance, behavior 4Tropical fish a threat to Mediterranean Sea ecosystems 2
... time of the Babylonians to the Incas, terracing has ... hilly croplands. Designing terrace layouts can be time consuming ... developing a Web-based program that will design multiple farm ... help farm experts choose the most efficient and cost-effective ...
... think of Earth as a nurturing place, straining mightily to maintain ... Gaia hypothesis, named for the ancient Greek goddess of Earth, even ... of giant organism, with its complex systems finely tuned to compensate ... is the Gaia view that is out of kilter, says Peter ...
... National Institutes of Health is launching the first ... for rare and neglected diseases. The $24 million ... for Rare and Neglected Diseases Program, or TRND. ... spring, is unusual because TRND creates a drug ...
Cached Biology News:Web-based program designs more efficient farm terrace layouts 2New book suggests Earth perhaps not such a benevolent mother after all 2New book suggests Earth perhaps not such a benevolent mother after all 3NIH announces new program to develop therapeutics for rare and neglected diseases 2NIH announces new program to develop therapeutics for rare and neglected diseases 3NIH announces new program to develop therapeutics for rare and neglected diseases 4NIH announces new program to develop therapeutics for rare and neglected diseases 5
Ca2+ Channel Ca gamma 2 Purified Anti-Mouse, Anti-Rat, Anti-Human clone Polyclonal, Isotype Rabbit Ig, 50 µl Consult technical datasheet for details....
Rabbit polyclonal to SMURF 2 ( Abpromise for all tested applications). Antigen: A KLH conjugated synthetic peptide (10-30 aa in length) at the N-term of first 50 aa of human SMURF 2. Entrez G...
Goat polyclonal to Centaurin alpha 2**...
... immobilization can be coupled with a ligand such ... create an affinity matrix of choice. Affi-Gel 10 ... amines. Affi-Gel 10 gel couples neutral or basic ... 15 gel couples acidic proteins with pI less ...
Biology Products: